|Bid||275.000 x 100|
|Ask||275.420 x 100|
|Day's Range||274.010 - 283.100|
|52 Week Range||155.000 - 298.150|
|PE Ratio (TTM)||27.52|
|Earnings Date||Apr 17, 2018|
|Forward Dividend & Yield||5.12 (1.79%)|
|1y Target Est||262.00|
W.W. Grainger (GWW) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding GWW totaled $2.58 billion.
Forecast-topping Q4 earnings performance, upbeat guidance, pricing initiatives and have contributed to the rally in Grainger's (GWW) shares.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Industrials sector is rising.
Today we’re going to take a look at the well-established WW. Grainger Inc. (NYSE:GWW). The company’s stock saw a double-digit share price rise of over 10% in the past coupleRead More...
CHICAGO , March 2, 2018 /PRNewswire/ -- Grainger (NYSE: GWW), the leading broad line supplier of maintenance, repair and operating (MRO) products serving businesses and institutions, today announced that ...
W.W. Grainger Inc (NYSE:GWW) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Apart from strong Q4 results, upbeat guidance and price performance ahead of the industry, what are the other factors that make W.W. Grainger (GWW) a must-add to your portfolio. Read on to find out.
W.W. Grainger (GWW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: W.W. Grainger, Lennar, Ulta Beauty, Seagate and International Paper
Data from as early as 1950 showed that the 12-month return on the broader S&P 500 in the Year of the Dog was up more than 15% on average.
Have you been keeping an eye on WW Grainger Inc’s (NYSE:GWW) upcoming dividend of $1.28 per share payable on the 01 March 2018? Then you only have 3 days leftRead More...
CHICAGO , Jan. 31, 2018 /PRNewswire/ -- The board of directors of W.W. Grainger, Inc. (NYSE: GWW) declared a cash dividend of $1.28 per share payable on March 1, 2018 , to shareholders of record on Feb. ...
Stock Monitor: Fastenal Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 30, 2018 / Active-Investors.com has just released a free earnings report on W.W. Grainger, Inc. (NYSE: GWW ) ("Grainger"). ...
CHICAGO, Jan. 29, 2018 /PRNewswire/ -- Grainger (GWW), the leading broad line supplier of maintenance, repair and operating (MRO) products serving businesses and institutions, is again named to Fortune's annual list of "World's Most Admired Companies" for 2018. "It's an honor to earn a spot on Fortune's 2018 'World's Most Admired Companies' list, and we're very proud to rank number one in our category for the fifth year in a row," said Grainger Chairman and Chief Executive Officer, DG Macpherson. Fortune's "World's Most Admired Companies" list is a definitive report card on corporate reputations.
Over the last month, growth of ETFs holding GWW is favorable, with net inflows of $16.16 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
On a mixed day for the indexes, United Continental lost altitude after analysts questioned its growth plan, and W.W. Grainger soared on a strong profit report.
W.W. Grainger (GWW) soared to the top of the S&P 500 on Wednesday, thanks to its better-than-expected fourth-quarter earnings and guidance. Analysts were looking for earnings of $2.19 on revenue of $2.57 billion. For the full year, it expects earnings between $12.95 and $14.15, on revenue of $10.74 billion to $11.15 billion.
Jim Cramer flew through his take on callers' favorite stocks, including a pharmaceutical play undergoing a turnaround.